An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)
NCT ID: NCT01358942
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
156 participants
OBSERVATIONAL
2011-05-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed non-small cell lung cancer
* Initiating first-line treatment with standard platinum-based chemotherapy, with or without bevacizumab
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vitoria-Gasteiz, Alava, Spain
Alcoy, Alicante, Spain
Alicante, Alicante, Spain
Elche, Alicante, Spain
Elda, Alicante, Spain
Mahon, Balearic Islands, Spain
Palma de Mallorca, Balearic Islands, Spain
Palma de Mallorca, Balearic Islands, Spain
Barcelona, Barcelona, Spain
Barcelona, Barcelona, Spain
Barcelona, Barcelona, Spain
Jerez de la Frontera, Cadiz, Spain
Castellon, Castellon, Spain
Donostia / San Sebastian, Guipuzcoa, Spain
Jaén, Jaen, Spain
Logroño, La Rioja, Spain
Alcalá de Henares, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Madrid, Madrid, Spain
Málaga, Malaga, Spain
Melilla, Malaga, Spain
Navarra, Navarre, Spain
Pamplona, Navarre, Spain
Pamplona, Navarre, Spain
Tudela, Navarre, Spain
Pontevedra, Pontevedra, Spain
Oviedo, Principality of Asturias, Spain
Segovia, Segovia, Spain
Sagunto, Valencia, Spain
Valencia, Valencia, Spain
Valencia, Valencia, Spain
Xàtiva, Valencia, Spain
Bilbao, Vizcaya, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML25493
Identifier Type: -
Identifier Source: org_study_id